文献速递免疫规划传染病防控与疫情报告

M蛋白缺失RSV疫苗经鼻或肺内接种改善婴儿狒狒感染后症状并减少病毒复制

Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection.
PubMed 文献 · Vaccine · 2021-06-14

研究以2周龄婴儿狒狒为对象,比较鼻内(IN)与气管内(IT)接种M蛋白缺失RSV疫苗后经人RSV肺内攻击的效果。IT接种诱导更强且持续4-6个月的血清中和抗体,感染后呼吸急促与呼吸做功改善更明显,BAL液中病毒不可检出;IN接种抗体反应不一致但中度减少呼吸频率、总体症状与病毒复制。结果支持进一步开发IT途径Mnull RSV疫苗。

要点

  • IT接种Mnull RSV诱导更强且持续4-6个月的血清中和抗体。
  • IT接种后RSV攻击时BAL液病毒不可检出,呼吸症状改善优于IN。
  • IN接种抗体反应不一致,仅中度减少呼吸频率、症状与病毒复制。

核心结论

  • 气管内接种Mnull RSV疫苗在婴儿狒狒中诱导更强持久的中和抗体并显著减少攻击后病毒复制与临床症状。

研究设计与样本

  • 研究以2周龄婴儿狒狒为对象,分别经鼻内(IN)或气管内(IT)接种Mnull RSV疫苗,随后经肺内接种人RSV进行攻击感染。

主要发现

  • IN接种诱导的血清RSV中和抗体反应不一致,但感染后呼吸频率、总体疾病症状和BAL液病毒复制呈中度减少。
  • IT接种诱导的RSV中和抗体反应更强,且至少持续4-6个月。
  • IT接种动物感染后呼吸急促和呼吸做功的改善程度远大于IN接种动物,且BAL液中检测不到病毒。

临床怎么用

  • 结果支持进一步开发经气管内接种的Mnull RSV疫苗以降低人RSV感染的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Respiratory syncytial virus (RSV) is the major viral respiratory pathogen for human infants and children. Despite a severe global burden incurred by annual RSV epidemics, there is no licensed RSV vaccine. We have developed an RSV vaccine from a human RSV strain from which the gene for the viral M protein has been deleted ("Mnull RSV"). RSV infects airway cells and produces each of its proteins. The M protein is responsible for reassembling the various other synthesized viral proteins into new, intact virus. In the absence of the M protein, therefore, reassembly does not occur, and the Mnull RSV does not replicate. We vaccinated 2-week old infant baboons with Mnull RSV either intranasally (IN) or directly into the lung (intratracheal, or IT), then infected these animals by inoculating human RSV directly into the lung. IN vaccination induced inconsistent serum RSV neutralizing antibody (NA) responses, but provided moderate reductions in respiratory rates, overall signs of illness and viral replication in bronchoalveolar lavage (BAL) fluid following infection. Intratracheal vaccination induced much stronger RSV NA responses, which persisted for at least 4-6 months. Following RSV infection, animals vaccinated by the IT route had much greater reductions in tachypnea and work of breathing than animals vaccinated IN, and had undetectable amounts of virus in BAL fluids. These results support the further development of IT Mnull RSV vaccination to reduce the impact of RSV infection in humans.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ivanov V, Oomens AGP, Papin JF, et al. Intranasal and intrapulmonary vaccination with an M protein-deficient respiratory syncytial virus (RSV) vaccine improves clinical signs and reduces viral replication in infant baboons after an RSV challenge infection. Vaccine. 2021. PMID: 34140172. doi:10.1016/j.vaccine.2021.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。